Enzymatica, which develops and sells medical products based on an enzyme from deep-sea cod, is announcing today that its partner Adartis Animal Health has placed a first order for the veterinary products launched in the United States and Canada in July. The order includes KalvatinTM products to a value of about SEK 3 million and is expected to cover market needs for the next six to twelve months. The first part delivery will be made in the fourth quarter of 2014 and is expected to have a positive impact on earnings of more than SEK 1 million.
“Our partner has recently started the work of introduction and the market is in the build-up phase. We look forward to following the activities in the market during the coming fall and winter. Veterinary products broaden our product portfolio and provide a long term opportunity to grow in a new segment,” says Christian W. Jansson, acting CEO of Enzymatica.
The KalvatinTM products are marketed and sold in North America by Enzymatica’s partner Adartis Animal Health. The products target companion animal veterinary clinics. In the United States and Canada, there are about 44,000 veterinary clinics.*
Kalvatin Dermal and Kalvatin Dental are enzyme-based products for treating skin and gum infections, primarily in dogs and cats. The spray/gel creates a protective surface barrier that prevents bacteria from causing infection. Development has been on the same technology platform as Enzymatica’s common cold product ColdZyme®.
The Kalvatin products were launched at the AVMA Annual Convention in Denver, USA on July 25-29, 2014.
For more information, please contact:
Christian W Jansson, acting CEO Enzymatica AB
Phone: +46 706 37 12 58. E-mail: firstname.lastname@example.org
Tina Dackemark Lawesson, Senior Communications Officer Enzymatica AB
Phone: +46 46 286 31 00. E-mail: email@example.com
* American Pet Products Associations website 2014.
About Enzymatica AB (publ)
Enzymatica AB (publ) develops and sells medical technology products based on an enzyme from deep-sea cod. They include medical devices for upper respiratory infections and oral health, and veterinary products in oral health and dermatology. The medical portfolio includes ColdZyme® against common colds. The company is headquartered in Lund, Sweden, and is listed on Aktietorget. For more information, please visit www.enzymatica.com.